Brief: Verve Therapeutics Announces Dosing of First Patient in Heart-2 Phase 1b Clinical Trial Evaluating VERVE-102

Verve Therapeutics

07/05/2024 12:40

May 7 (Reuters) - Verve Therapeutics Inc  VERV.O :
    * VERVE THERAPEUTICS ANNOUNCES DOSING OF FIRST PATIENT IN
HEART-2
PHASE 1B CLINICAL TRIAL EVALUATING VERVE-102
    * VERVE THERAPEUTICS INC - HEART-2 ENROLLING PATIENTS WITH
HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA OR PREMATURE CORONARY
ARTERY DISEASE

Source text for Eikon:  ID:nGNX2gW7B5 
Further company coverage:  VERV.O 

 ((Reuters.Briefs@thomsonreuters.com;))